Teva Pharmaceutical Industries Limited TEVA
42.40 USD -0.57 (-1.33%)
At closeNov 11, 2026, 6:16 AM EST
42.51 +0.11 +0.26%
Pre-market · Nov 11, 6:16 AM ET
41.65 Day range 42.69
24.01 52-week range 43.34
- YTD
- +35.85%
- 1 year
- +68.72%
News
fool.com Teva's 3 Key Branded Drugs Grew Sales 33% Last Quarter. Is This Turnaround Stock a Buy Right Now? Teva improved margins significantly. The pharmaceutical company has paid down net debt.
defenseworld.net What Teva Pharmaceutical Industries (TEVA) Said on Its Q3 Earnings Call Teva Pharmaceutical Industries (NYSE: TEVA) reported third-quarter 2026 revenue of approximately $4.4 billion, down 2% from a year earlier, as growth in its innovative medicines portfolio was offset…
benzinga.com Leerink Partners Maintains Outperform on Teva Pharmaceutical Indus, Raises Price Target to $52 Leerink Partners analyst Daniel Clark maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Outperform and raises the price target from $45 to $52.
benzinga.com TD Cowen Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $57 TD Cowen analyst Joseph Thome maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises the price target from $55 to $57.
zacks.com Teva Q3 Earnings Beat Estimates, 2026 Revenue View Raised, Stock Up Teva's Q3 earnings beat estimates as strong branded drug sales fueled growth, prompting higher 2026 revenue and product sales guidance.
benzinga.com MindWalk Holdings Inks Agreement With Teva Pharmaceuticals Australia To Deploy ReefIQ MindWalk Holdings Corp. ("MindWalk") (NASDAQ: HYFT), a Bio-Native AI company, today announced a multi-year agreement with Teva Pharmaceuticals Australia Pty Ltd ("Teva Australia") to deploy ReefIQ™,
benzinga.com HC Wainwright & Co. Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $54 HC Wainwright & Co. analyst Douglas Tsao maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises the price target from $52 to $54.
marketbeat.com What Teva Pharmaceutical Industries (TEVA) Said on Its Q3 Earnings Call Teva Pharmaceutical Industries NYSE: TEVA reported third-quarter 2026 revenue of approximately $4.4 billion, down 2% from a year earlier, as growth in its innovative medicines portfolio was offset by…
benzinga.com Teva CEO Sees Strong Austedo Demand Cushioning Medicare Pricing Blow in 2027 Teva stock jumps after beating Q3 earnings and boosting its 2026 outlook, powered by 33% branded drug growth.
benzinga.com Teva Pharmaceutical Indus Q3 2026 Earnings Call Transcript Teva Pharmaceutical Indus (NYSE:TEVA) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com Teva Pharmaceutical Indus Raises FY2026 Adj EPS Guidance from $1.91-$2.11 to $1.92-$2.11 vs $1.98 Est; Raises FY2026 Sales Guidance from $16.500B-$16.850B to $16.700B-$17.000B vs $16.651B Est Teva Pharmaceutical Indus (NYSE:TEVA) raises FY2026 Adj EPS guidance from $1.91-$2.11 to $1.92-$2.11 vs $1.98 analyst estimate. Raises FY2026 sales outlook from $16.500 billion-$16.850 billion to…- benzinga.com Teva Pharmaceutical Indus Q3 Adj. EPS $0.86 Beats $0.73 Estimate, Sales $4.395B Beat $4.291B Estimate Teva Pharmaceutical Indus (NYSE:TEVA) reported quarterly earnings of $0.86 per share which beat the analyst consensus estimate of $0.73 by 17.81 percent. This is a 10.26 percent increase over…
benzinga.com Teva Expands Samsung Bioepis Collaboration With ETICOVO, Infliximab-Abda Deal; Upfront Payment Over 3 Years, Launch And Sales Milestones Possible, Profits Shared Teva to obtain U.S. commercialization rights for two immunology biosimilars: ETICOVO® upon close and infliximab-abda in Q3 2027Collaboration combines Samsung Bioepis’ biosimilar expertise with Teva’s…
benzinga.com AMD, Shopify On Deck Tuesday As AI Spending, Merchant Growth Face Test Advanced Micro Devices headlines Tuesday’s reports, with investors looking for evidence that AI demand can withstand a sharp pullback in the stock. Shopify, Pfizer, Eaton, Marathon Petroleum and…
benzinga.com Why Is Teva Stock Trading Lower on Monday? Teva halts its Phase 2 TOPAS-MSA study after an interim futility analysis showed low odds of meeting the primary efficacy endpoint.
benzinga.com This GameStop Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Analysts initiated bullish coverage on Janus Living, GameStop, SharkNinja, Teva and H2O America, with targets of $33, $33, $245, $52 and $67.- benzinga.com HC Wainwright & Co. Initiates Coverage On Teva Pharmaceutical Indus with Buy Rating, Announces Price Target of $52 HC Wainwright & Co. analyst Douglas Tsao initiates coverage on Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy rating and announces Price Target of $52.
benzinga.com Teva Pharmaceuticals International GmbH Acquires BioXcel Therapeutics' Assets For $57.5M Upfront Payment Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that it has completed the acquisition of assets from BioXcel…- benzinga.com Teva Pharma And Sanofi Report Duvakitug Maintained Efficacy Through 44 Weeks In Ulcerative Colitis And Crohn's Disease In UC, duvakitug maintained high rates of clinical remission, clinical response, and endoscopic improvement at Week 44In CD, duvakitug maintained high rates of endoscopic response, clinical response,…
- benzinga.com Barclays Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $47 Barclays analyst Glen Santangelo maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target from $42 to $47.